吡非尼酮治疗癌症患者2或3级放射性肺损伤的成本效果模型研究
基于II期随机试验(NCT03902509)个体数据构建Markov模型,评估吡非尼酮联合糖皮质激素对比单用糖皮质激素治疗2或3级放射性肺损伤的成本效果。结果显示联合治疗每获得1个QALY需增量成本20956美元,远低于100000美元/QALY的支付意愿阈值,概率敏感性分析显示99.98%概率具有成本效果。
要点
- 吡非尼酮联合糖皮质激素较单用糖皮质激素增量成本590美元,增量QALY为0.028。
- ICER为20956美元/QALY,低于常用WTP阈值100000美元/QALY。
- 概率敏感性分析显示联合治疗具有成本效果的概率为99.98%。
核心结论
- 对于2或3级放射性肺损伤,吡非尼酮联合糖皮质激素对比单用糖皮质激素具有成本效果。
研究设计与样本
- 基于II期随机临床试验(NCT03902509)个体数据构建Markov模型,模拟4周周期、24周时间跨度。
- 成本与效用按每年3%贴现,健康结局用增量成本效果比(ICER)表示每获得1个质量调整生命年(QALY)的增量成本。
主要发现
- 与单用糖皮质激素相比,吡非尼酮联合糖皮质激素增量成本590美元,额外获得0.028 QALYs。
- ICER为20956美元/QALY,远低于常用支付意愿阈值100000美元/QALY。
- 单因素敏感性分析中,对ICER影响最大的变量包括无急性肺 exacerbation生存期和糖皮质激素组2或3级RILI患者无应答概率。
- 概率敏感性分析显示,在100000美元/QALY阈值下联合治疗具有成本效果的概率为99.98%。
关键数值与推荐
- ICER为20956美元/QALY,低于100000美元/QALY的支付意愿阈值。
- 增量成本590美元,增量QALY为0.028。
临床怎么用
- 对于2或3级放射性肺损伤患者,吡非尼酮联合糖皮质激素可作为具有成本效果的临床管理选项。
局限性
- 基于II期试验数据,样本量有限且随访时间较短。
- 正在进行的III期试验将提供进一步证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cost-effective treatment strategy for radiation-induced lung injury (RILI) remains unclear. Our recent phase II randomized clinical trial has proved pirfenidone to be safe and effective for grade 2 or 3 RILI. Here, we aim to assess the cost-effectiveness of pirfenidone plus glucocorticoids versus glucocorticoids alone for the treatment of grade 2 or 3 RILI. METHODS AND FINDINGS: We constructed a Markov model based on the individual-level data from our trial (NCT03902509) to evaluate the cost-effectiveness of pirfenidone plus glucocorticoids. Outcomes were simulated in a 4-week cycle over a 24-week time horizon to model patients who had acute pulmonary exacerbation or RILI progression. Costs and utilities were discounted at 3% annually. Health outcomes were measured using incremental cost-effectiveness ratio (ICER), representing incremental costs per quality-adjusted life year (QALY) gained between the two treatment groups. One-way and probabilistic sensitivity analyses were conducted to evaluate the model uncertainties. The simulated RILI pattern in the Markov model closely matched the pattern in the trial cohort, indicating that the model accurately described the disease process of RILI. Compared with glucocorticoids alone, pirfenidone plus glucocorticoids yielded an additional 0.028 QALYs at an incremental cost of $590, with an ICER of $20,956 per QALY gained. The ICER was considerably below the commonly accepted willingness-to-pay (WTP) threshold of $100,000 per QALY. In one-way sensitivity analyses, the variables with the greatest influence on the ICER included the acute pulmonary exacerbation-free survival and the probability of non-response among patients with grade 2 or 3 RILI in glucocorticoid group. Moreover, the probabilistic sensitivity analysis demonstrated that pirfenidone plus glucocorticoids had a 99.98% probability of being cost-effective at the WTP threshold of $100,000/QALY. Limitations include the phase II trial data with limited sample size and follow-up. An ongoing phase III trial will provide further evidence. CONCLUSIONS: For grade 2 or 3 RILI, pirfenidone plus glucocorticoids is cost-effective compared with glucocorticoids alone. This strategy offers a practical and evidence-based option for RILI clinical management.
引用
- Pan QY, Wang YX, Tang XY, et al. Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study. PLoS Med. 2026. PMID: 42555672. doi:10.1371/journal.pmed.1004817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。